Literature DB >> 21672035

p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance.

Xiangkun Hu1, Yuan Ruan, Fan Cheng, Weimin Yu, Xiaobin Zhang, Stéphane Larré.   

Abstract

OBJECTIVES: To investigate the effects of junction protein, p130 Crk-associated substance (p130Cas), and adhesion molecules, E-cadherin and β-catenin, on the biological behavior of transitional cell carcinoma of the bladder.
METHODS: In 72 paraffin embedded specimens of transitional cell carcinoma of the bladder and 20 normal controls, the expression of p130Cas, E-cadherin and β-catenin was examined by quantum dot-based immunofluorescence histochemistry (QD-IHC) and conventional immunohistochemistry (IHC).
RESULTS: QD-IHC was consistent with IHC in detecting the expression of the three molecules (P > 0.05 for all comparisons). The positive expression rate of p130Cas in bladder cancer tissues increased more significantly than that in normal bladder tissues (P < 0.001). Similarly, the aberrant expression rates of E-cadherin and β-catenin in bladder cancer tissues were significantly higher than those in normal bladder tissues (P < 0.001 for both comparisons). The expression of each molecule was correlated with tumor pathological grade and clinical stage (P < 0.05 for all comparisons), but not with tumor number and size (P > 0.05 for all comparisons). Furthermore, negative correlations were found between the expression intensities of p130Cas and E-cadherin or β-catenin in transitional cell carcinoma of the bladder (P < 0.05 for both comparisons).
CONCLUSIONS: p130Cas, E-cadherin and β-catenin might represent useful predictors of malignant degree of transitional cell carcinoma of the bladder.
© 2011 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672035     DOI: 10.1111/j.1442-2042.2011.02793.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

1.  LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC).

Authors:  Dechao Jiao; Zongming Li; Ming Zhu; Yanli Wang; Gang Wu; Xinwei Han
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells.

Authors:  Julia Schulte; Michaela Weidig; Philipp Balzer; Petra Richter; Marcus Franz; Kerstin Junker; Mieczyslaw Gajda; Karlheinz Friedrich; Heiko Wunderlich; Arne Östman; Iver Petersen; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2012-07-22       Impact factor: 4.304

3.  Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas.

Authors:  Wei Tian; Guowen Wang; Jilong Yang; Yi Pan; Yulin Ma
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

4.  WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Authors:  Wolfgang Otto; Johannes Breyer; Sonja Herdegen; Fabian Eder; Simone Bertz; Matthias May; Roman Mayr; Eva M Lausenmeyer; Stefan Denzinger; Bas W G van Rhijn; Maximilian Burger; Arndt Hartmann
Journal:  Int Urol Nephrol       Date:  2016-12-29       Impact factor: 2.370

5.  A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Authors:  Maha Hussain; Stephanie Daignault; Neeraj Agarwal; Petros D Grivas; Arlene O Siefker-Radtke; Igor Puzanov; Gary R MacVicar; Ellis Glenn Levine; Sandy Srinivas; Przemyslaw Twardowski; Mario A Eisenberger; David I Quinn; Ulka N Vaishampayan; Evan Y Yu; Scott Dawsey; Kathleen C Day; Mark L Day; Mahmoud Al-Hawary; David C Smith
Journal:  Cancer       Date:  2014-05-06       Impact factor: 6.860

6.  Inhibition of mouse urinary bladder carcinogenesis by açai fruit (Euterpe oleraceae Martius) intake.

Authors:  Mariana F Fragoso; Monize G Prado; Luciano Barbosa; Noeme S Rocha; Luis F Barbisan
Journal:  Plant Foods Hum Nutr       Date:  2012-09       Impact factor: 3.921

7.  Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer.

Authors:  Makito Miyake; Yasushi Nakai; Satoshi Anai; Yoshihiro Tatsumi; Masaomi Kuwada; Sayuri Onishi; Yoshitomo Chihara; Nobumichi Tanaka; Yoshihiko Hirao; Kiyohide Fujimoto
Journal:  Cancer Sci       Date:  2014-04-06       Impact factor: 6.716

8.  MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer.

Authors:  Chia-Lun Wu; Jar-Yi Ho; Sheng-Chieh Chou; Dah-Shyong Yu
Journal:  Oncotarget       Date:  2016-05-03

9.  Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Authors:  Makito Miyake; Adrienne Lawton; Yunfeng Dai; Myron Chang; Lourdes Mengual; Antonio Alcaraz; Steve Goodison; Charles J Rosser
Journal:  BMC Cancer       Date:  2014-02-13       Impact factor: 4.430

10.  Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.

Authors:  Ricardo L Favaretto; Atessa Bahadori; Romain Mathieu; Andrea Haitel; Bernhard Grubmüller; Vitaly Margulis; Jose A Karam; Morgan Rouprêt; Christian Seitz; Pierre I Karakiewicz; Isabela W Cunha; Stenio C Zequi; Christopher G Wood; Alon Z Weizer; Jay D Raman; Mesut Remzi; Nathalie Rioux-Leclercq; Solene Jacquet-Kammerer; Karim Bensalah; Yair Lotan; Alexander Bachmann; Michael Rink; Alberto Briganti; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-29       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.